Role of pelvic lymphadenectomy in the management of Stage I endometrial cancer: Our experience

E. Vizza, G. M. Galati, G. Corrado, C. Sbiroli

Research output: Contribution to journalArticle

Abstract

Objectives: To estimate the prognostic value of pelvic-node removal on survival of patients affected by endometrial carcinoma at presurgical FIGO Stage I. Methods: A retrospective analysis was performed on a total of 111 patients recruited from 1990 to 1996 at the S. Carlo di Nancy Hospital. Thirty-nine (35%) of them underwent a total hysterectomy and bilateral salpingo-oophorectomy with removal of the vaginal cuff (group 1), while 72 (65%) underwent a total hysterectomy combined with pelvic lymphadenectomy (group 2). Prognostic features including tumor grade, depth of myometrial invasion and histologic subtype. Survival rates were calculated with Cox and Kaplan analyses. Results: Overall survival rate at five years was 91.2%. The survival rate of group 1 and group 2 was 89% and 92.8%, respectively which is not statistically significant. Stage, grade, histotype, age at diagnosis, and presence of positive lymph nodes did not show any significant prognostic value on survival probability. Conclusions: The survival rate for patients submitted to lymphadenectomy (group 2) was the same of patients who did not undergo this treatment (group 1). Nevertheless, pelvic lymphadenectomy in endometrial carcinoma at presurgical FIGO stage I was worthwhile as it allowed correct staging to be performed. The prediction of nodal disease based only on preoperative investigations (such as TC, NMR) is often inaccurate.

Original languageEnglish
Pages (from-to)126-128
Number of pages3
JournalEuropean Journal of Gynaecological Oncology
Volume24
Issue number2
Publication statusPublished - 2003

Keywords

  • Endometrial cancer
  • Lymphadenectomy
  • Staging
  • Total abdominal hysterectomy

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Fingerprint Dive into the research topics of 'Role of pelvic lymphadenectomy in the management of Stage I endometrial cancer: Our experience'. Together they form a unique fingerprint.

  • Cite this